1145409

FORM D



UNITED STATES FURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM D

03035707

'E OF SALE OF SECURITIES PURSUANT TO REGULATION D, SECTION 4(6), AND/OR UNIFORM LIMITED OFFERING EXEMPTION

OMB APPROVAL			
OMB NUMBER:	3235-0076		
Expires:	May 30, 2005		
Estimated average burden	·		
hours per response	1.00		

	SEC USE ONLY	
Prefix	Serial	
	DATE RECEIVED	
	<u> </u>	
-		
4(6) □ ULOE	SUBMED (CAMED)	

JLOE A GENED CO
007 0000
UC 1 2 W 2003 }
187/59
hone Number (Including Area Code)
54-9311
hone Number (Including Area Code)
PROCESSED
er (please specify): 0CT 21 2003
, 30.
<u>THOMSON</u>
FINANCIAL

GENERAL INSTRUCTIONS

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 USC 77d(6).

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

When to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State: This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires a payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

 Enter the information requested for t Each promoter of the issuer, if 	the issuer has be			<i>-</i>	
 Each beneficial owner having t Each executive officer and dire Each general and managing part 	ector of corporat	e issuers and of corporate			lass of equity securities of the issuer; ship issuers; and
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	■ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)				-	
Dukin Boul D					
Rubin, Paul D. Business or Residence Address	(Number and	Street, City, State, Zip Co	de)		
c/o Critical Therapeutics, Inc., 675 Mas					
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	■ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Warren, Howland S.					
Business or Residence Address	(Number and	Street, City, State, Zip Co	de)		
c/o Critical Therapeutics, Inc., 675 Mas	cachusatte Ava	nue 14 th floor Combrid	σο MA 02130		
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)	B 170moter	Delicited owner	E Exceutive Officer	Bilector	B General and of Wanaging Farance
,					
Galakatos, Nicholas Business or Residence Address	(Mount as and C	Street, City, State, Zip Coo	4		
Business of Residence Address	(Number and 3	street, City, State, Zip Coo	ue)		
c/o MPM Asset Management LLC, 111	Huntington Av	enue, Boston, MA 02199			
Check Box(es) that Apply:	□ Promoter	□ Beneficial Owner	Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Mirabelli, Christopher					
Business or Residence Address	(Number and S	Street, City, State, Zip Coo	de)		
/ W 14 G W	a	361.00540			
c/o HealthCare Ventures VI, L.P., 44 N Check Box(es) that Apply:	assau Street, Pi ☐ Promoter	Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)	Promotes	Beneficial Owner	L Executive Officer	Director	General and/or Managing Farmer
Tun Hame (East hame 1113t, 11 morrisday)					
Tracey, Kevin J.					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		
c/o Critical Therapeutics, Inc., 675 Mas	sachusetts Ave	nue, 14th floor, Cambrid	ge, MA 02139		
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Walsh, Christopher					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		
	,				
c/o Critical Therapeutics, Inc., 675 Mas					
Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Fink, Mitchell P.					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		
109 Rockwood Drive, Pittsburgh, PA 1	5238				
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)	_ I Tolllott	- Deficite at Owner	a Laccutive Officer	_ Director	2 Soliciai and of Hanaging Lather
, , , , , , , , , , , , , , , , , , ,					
MPM BioVentures II – Q.P., L.P.	(Museline 1	Street City Street 7' C	odo)		
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		
ale MDM Asset Management TTC 111	TT	D MA 0210	n		

A. BASIC IDENTIFICATION DATA

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

A. BASIC IDENTIFICATION DATA Enter the information requested for the following:

Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer; Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and Each general and managing partner of partnership issuers. Check Box(es) that Apply: □ Promoter ■ Beneficial Owner ☐ Executive Officer □ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) MPM BioVentures GmbH + Co. Parallel Beteiligungs KG Business or Residence Address (Number and Street, City, State, Zip Code) c/o MPM Asset Management LLC, 111 Huntington Avenue, Boston, MA 02199 Check Box(es) that Apply: □ Promoter ■ Beneficial Owner ☐ Executive Officer □ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) HealthCare Ventures VI, L.P. Business or Residence Address (Number and Street, City, State, Zip Code) 44 Nassau Street, Princeton, MA 08542 Check Box(es) that Apply: □ Promoter ■ Beneficial Owner ☐ Executive Officer □ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Seahorse Investments LLC Business or Residence Address (Number and Street, City, State, Zip Code) c/o Walter Newman, 3 Durham Street #3, Boston, MA 02115 Check Box(es) that Apply: □ Promoter ■ Beneficial Owner □ Executive Officer ☐ General and/or Managing Partner □ Director Full Name (Last name first, if individual) Johnson and Johnson Development Corporation Business or Residence Address (Number and Street, City, State, Zip Code) One Johnson & Johnson Plaza, New Brunswick, NJ 08933 Attn: Ting Pau Oei Check Box(es) that Apply: ■ Beneficial Owner ☐ General and/or Managing Partner □ Promoter □ Executive Officer □ Director Full Name (Last name first, if individual) Advanced Technology Ventures VII, L.P. (Number and Street, City, State, Zip Code) Business or Residence Address 1000 Winter Street, Suite 3700, Waltham, MA 02451 Attn: Jean George Check Box(es) that Apply: ☐ Promoter ■ Beneficial Owner □ Executive Officer □ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) MedImmune Ventures, Inc. Business or Residence Address (Number and Street, City, State, Zip Code) 35 West Watkins Mill Road, Gaithersburg, MD 20878 Check Box(es) that Apply: □ Executive Officer □ Promoter □ Beneficial Owner ■ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual)

Oei, Ting Pau Business or Residence Address (Number and Street, City, State, Zip Code) c/o Johnson and Johnson Development Corporation, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 Check Box(es) that Apply: □ Promoter □ Beneficial Owner □ Executive Officer ■ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) George, Jean Business or Residence Address (Number and Street, City, State, Zip Code) c/o Advanced Technology Ventures VII, L.P., 1000 Winter Street, Suite 3700, Waltham, MA 02451

	B. INFORMATION ABOUT OFFERING		
		Yes	No
1.	Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering?	. 🗆	
2.	Answer also in Appendix, Column 2, if filing under ULOE. What is the minimum investment that will be accepted from any individual?	. \$	n/a
۷.	what is the minimum investment that will be accepted from any individual:	Yes	No
3.	Does the offering permit joint ownership of a single unit?		
4.	Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.	•	
Full None	Name (Last name first, if individual)		
	ess or Residence Address (Number and Street, City, State, Zip Code)		
Dusi	ess of Residence Address (Number and Street, City, State, Zip Code)		
Nam	of Associated Broker or Dealer		
State	s in which Person Listed Has Solicited or Intends to Solicit Purchasers (Check "All States" or check individual States)	☐ All States	
ſ.			шл
_ (A _ [] _ [] _ []	L] _ [IN] _ [IA] _ [KS] _ [KY] _ [LA] _ [ME] _ [MD] _ [MA] _ [MI] _ [MI 1T] _ [NE] _ [NV] _ [NH] _ [NJ] _ [NM] _ [NY] _ [NC] _ [ND] _ [OH] _ [OH	N] _ [MS] K] _ [OR]	_ [ID] _ [MO] _ [PA] _ [PR]
Full	name (Last name first, if individual)		
Busi	ess or Residence Address (Number and Street, City, State, Zip Code)		
Nam	of Associated Broker or Dealer		
State	s in which Person Listed Has Solicited or Intends to Solicit Purchasers		
	(Check "All States" or check individual States)	□ All States	
_ [/ _ [/ _ [/	L] _[IN] _ [IA] _ [KS] _ [KY] _ [LA] _ [ME] _ [MD] _ [MA] _ [MI] _ [MI] 1T] _[NE] _ [NV] _ [NH] _ [NJ] _ [NM] _ [NY] _ [NC] _ [ND] _ [OH] _ [OH] 1.1] _[SC] _ [SD] _ [TN] _ [TX] _ [UT] _ [VT] _ [VA] _ [WA] _ [WV] _ [WV]	N] _ [MS] K] _ [OR]	_ [ID] _ [MO] _ [PA] _ [PR]
Full	Name (Last name first, if individual)		
Busi	ess or Residence Address (Number and Street, City, State, Zip Code)		-
Nam	of Associated Broker or Dealer		
, vail	C. I Sporting Stories of Boards		
State	s in which Person Listed Has Solicited or Intends to Solicit Purchasers		
	(Check "All States" or check individual States)	☐ All States	
_ () _ () _ ()	L] _ [IN] _ [IA] _ [KS] _ [KY] _ [LA] _ [ME] _ [MD] _ [MA] _ [MI] _ [MI 1T] _ [NE] _ [NV] _ [NH] _ [NJ] _ [NM] _ [NY] _ [NC] _ [ND] _ [OH] _ [OH]	N] _ [MS] K] _ [OR]	_ [ID] _ [MO] _ [PA] _ [PR]

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

1.	already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box rand indicate in the columns below the amounts of the securities offered for exchange and already exchanged.	Aggregate Offering Price	Amount Already Sold
	Type of Security		
	Debt	\$	\$
	Equity	\$ <u>56,154,600.60</u>	\$ <u>27,828,655.40</u>
	□ Common ■ Preferred		
	Convertible Securities (including warrants)	\$	\$
	Partnership Interests	\$	\$
	Other (Specify)	\$	\$
	Total	\$ <u>56,154,600.60</u>	\$ <u>27,828,655.40</u>
	Answer also in Appendix, Column 3, if filing under ULOE.		
2.	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."	Number of Investors	Aggregate Dollar Amount of Purchases
	Accredited Investors	22	\$ <u>27,828,655.40</u>
	Non-accredited Investors	····	\$
	Total (for filings under Rule 504 only)		\$
	Answer also in Appendix, Column 4, if filing under ULOE		<u> </u>
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C – Question 1. Type of offering	Type of Security	Dollar Amount Sold
	Rule 505		\$
	Regulation A		\$
	Rule 504		\$
	Total		φ
	Total		\$
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
	Transfer Agent's Fees		\$
	Printing and Engraving Costs	D	\$
	Legal Fees	•	\$ <u>150,000</u>
	Accounting Fees		\$
	Engineering Fees		\$
	Sales Commissions (specify finders' fees separately)	_	\$
	Other Expenses (identify)		\$
	Total	.	\$ 150,000
			

 b. Enter the difference between the aggregate offering price given in response to Part C-1 and total expenses furnished in response to Part C – Question 4.a. This difference is th "adjusted gross proceeds to the issuer." 	e		\$_	56,004,600.60
Indicate below the amount of the adjusted gross proceeds to the issuer used or proposed to for each of the purposes shown. If the amount for any purpose is not known, furnish and and check the box to the left of the estimate. The total of the payments listed must equal adjusted gross proceeds to the issuer set forth in response to Part C – Question 4.b above	estimate the			
		Payments to Officers, Directors, & Affiliates		Payments To Others
Salaries and fees		\$	0	\$
Purchase of real estate		\$		\$
Purchase, rental or leasing and installation of machinery and equipment	0	\$	۵	\$
Construction or leasing of plant buildings and facilities	D	\$	ם	\$
Acquisition of other business (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a				
merger)		\$		\$
Repayment of indebtedness		\$		\$
Working capital		\$		\$
Other (specify):		\$	•	\$ <u>56,004,600.60</u>
	-	\$	_	\$
Column Totals		\$ 0		\$ <u>56,004,600.60</u>
Total Payments Listed (column totals added)		■ \$ <u>.5</u>	6,004,600	<u>.60</u>

The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502.

Issuer (Print or Type) Critical Therapeutics, Inc.	Signature	Date October 2, 2003
Name of Signer (Print or Type) Paul D. Rubin, M.D.	Title of Signer (Print or Type) Chief Executive Officer and President	

ATTENTION

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)